文献速递淋巴瘤MDS 与骨髓增殖性肿瘤

接受JAK1/2抑制剂治疗的骨髓纤维化患者中出现的侵袭性B细胞淋巴瘤

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.
PubMed 文献 · Blood · 2018-06-14

该研究评估626例骨髓增殖性肿瘤(MPN)患者,其中69例接受JAK1/2抑制剂治疗的骨髓纤维化患者中4例(5.8%)发生B细胞淋巴瘤,而557例常规治疗者仅2例(0.36%),风险增加16倍;独立队列929例MPN患者中观察到类似15倍增加。淋巴瘤为侵袭性B细胞型,常伴结外或白血病表现及高MYC表达,且无JAK2 V617F或其他MPN相关突变。

要点

  • JAK1/2抑制剂治疗的骨髓纤维化患者B细胞淋巴瘤发生率为5.8%(4/69),常规治疗为0.36%(2/557),风险增加16倍。
  • 独立队列929例MPN患者中观察到类似15倍增加。
  • 淋巴瘤为侵袭性B细胞型,常结外或白血病表现,高MYC表达,无JAK2 V617F或其他MPN相关突变。

核心结论

  • 骨髓纤维化中JAK/STAT1通路抑制与侵袭性B细胞淋巴瘤频率升高相关。
  • 检测预先存在的B细胞克隆可能识别高危个体。

研究设计与样本

  • 评估626例MPN患者,包括69例接受JAK1/2抑制剂的骨髓纤维化患者,观察淋巴瘤发生。
  • 另在独立队列929例MPN患者中验证。
  • 仅考虑原发性骨髓纤维化(N=216),31例抑制剂治疗患者中观察到3例淋巴瘤(9.7%),185例对照患者中1例(0.54%)。
  • Stat1-/-小鼠实验:24只中16只发生自发性髓系增生并伴异常B细胞。
  • 移植患病小鼠骨髓可揭示恶性B细胞克隆的出生长并演变为侵袭性B细胞白血病-淋巴瘤。

主要发现

  • 接受JAK1/2抑制剂的69例患者中4例(5.8%)发生B细胞淋巴瘤,而557例常规治疗患者中2例(0.36%),风险增加16倍。
  • 独立队列929例MPN患者中观察到类似15倍增加。
  • 淋巴瘤为侵袭性B细胞型、结外或白血病表现,高MYC表达,无JAK2 V617F或其他MPN相关突变。
  • 从启动抑制剂治疗至淋巴瘤诊断的中位时间为25个月。
  • 骨髓纤维化期间16.3%的患者骨髓中已检测到克隆性免疫球蛋白基因重排。

临床怎么用

  • 作者认为检测预先存在的B细胞克隆可能识别高危个体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inhibition of Janus-kinase 1/2 (JAK1/2) is a mainstay to treat myeloproliferative neoplasms (MPN). Sporadic observations reported the co-incidence of B-cell non-Hodgkin lymphomas during treatment of MPN with JAK1/2 inhibitors. We assessed 626 patients with MPN, including 69 with myelofibrosis receiving JAK1/2 inhibitors for lymphoma development. B-cell lymphomas evolved in 4 (5.8%) of 69 patients receiving JAK1/2 inhibition compared with 2 (0.36%) of 557 with conventional treatment (16-fold increased risk). A similar 15-fold increase was observed in an independent cohort of 929 patients with MPN. Considering primary myelofibrosis only (N = 216), 3 lymphomas were observed in 31 inhibitor-treated patients (9.7%) vs 1 (0.54%) of 185 control patients. Lymphomas were of aggressive B-cell type, extranodal, or leukemic with high MYC expression in the absence of JAK2 V617F or other MPN-associated mutations. Median time from initiation of inhibitor therapy to lymphoma diagnosis was 25 months. Clonal immunoglobulin gene rearrangements were already detected in the bone marrow during myelofibrosis in 16.3% of patients. Lymphomas occurring during JAK1/2 inhibitor treatment were preceded by a preexisting B-cell clone in all 3 patients tested. Sequencing verified clonal identity in 2 patients. The effects of JAK1/2 inhibition were mirrored in Stat1-/- mice: 16 of 24 mice developed a spontaneous myeloid hyperplasia with the concomitant presence of aberrant B cells. Transplantations of bone marrow from diseased mice unmasked the outgrowth of a malignant B-cell clone evolving into aggressive B-cell leukemia-lymphoma. We conclude that JAK/STAT1 pathway inhibition in myelofibrosis is associated with an elevated frequency of aggressive B-cell lymphomas. Detection of a preexisting B-cell clone may identify individuals at risk.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018. PMID: 29907599. doi:10.1182/blood-2017-10-810739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。